Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

TitleAssociation of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer
Publication TypeJournal Article
Year of Publication2011
AuthorsYang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W
JournalJAMA : the journal of the American Medical Association
Volume306
Pagination1557-65
Date PublishedOct 12
Type of ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov't
PMID21990299
Keywords*Genes, BRCA1, *Genes, BRCA2, *Mutation, Adult, Aged, Aged, 80 and over, Antineoplastic Agents/pharmacology, Databases, Factual, Disease Progression, DNA Methylation, Drug Resistance, Neoplasm, Female, Genomic Instability, Humans, Middle Aged, Ovarian Neoplasms/drug therapy/*genetics/*mortality, Phenotype, Prognosis, Promoter Regions, Genetic, Survival Analysis, Treatment Outcome
AbstractCONTEXT: Attempts to determine the clinical significance of BRCA1/2 mutations in ovarian cancer have produced conflicting results. OBJECTIVE: To determine the relationships between BRCA1/2 deficiency (ie, mutation and promoter hypermethylation) and overall survival (OS), progression-free survival (PFS), chemotherapy response, and whole-exome mutation rate in ovarian cancer. DESIGN, SETTING, AND PATIENTS: Observational study of multidimensional genomics and clinical data on 316 high-grade serous ovarian cancer cases that were made public between 2009 and 2010 via The Cancer Genome Atlas project. MAIN OUTCOME MEASURES: OS and PFS rates (primary outcomes) and chemotherapy response (secondary outcome). RESULTS: BRCA2 mutations (29 cases) were associated with significantly better OS (adjusted hazard ratio [HR], 0.33; 95% CI, 0.16-0.69; P = .003 and 5-year OS, 61% for BRCA2-mutated vs 25% for BRCA wild-type cases) and PFS (adjusted HR, 0.40; 95% CI, 0.22-0.74; P = .004 and 3-year PFS, 44% for BRCA2-mutated vs 16% for BRCA wild-type cases), whereas neither BRCA1 mutations (37 cases) nor BRCA1 methylation (33 cases) was associated with prognosis. Moreover, BRCA2 mutations were associated with a significantly higher primary chemotherapy sensitivity rate (100% for BRCA2-mutated vs 82% [P = .02] and 80% [P = .05] for BRCA wild-type and BRCA1-mutated cases, respectively) and longer platinum-free duration (median platinum-free duration, 18.0 months for BRCA2-mutated vs 11.7 [P = .02] and 12.5 [P = .04] months for BRCA wild-type and BRCA1-mutated cases, respectively). BRCA2-mutated, but not BRCA1-mutated cases, exhibited a "mutator phenotype" by containing significantly more mutations than BRCA wild-type cases across the whole exome (median mutation number per sample, 84 for BRCA2-mutated vs 52 for BRCA wild-type cases, false discovery rate <0.1). CONCLUSION: Among women with high-grade serous ovarian cancer, BRCA2 mutation, but not BRCA1 deficiency, was associated with improved survival, improved chemotherapy response, and genome instability compared with BRCA wild-type.
Short TitleJamaJama
Alternate JournalJama

Back